Does the media refer more to COGT or UTHR?

In the previous week, United Therapeutics had 26 more articles in the media than Cogent Biosciences. MarketBeat recorded 31 mentions for United Therapeutics and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat United Therapeutics' score of 1.43 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive United Therapeutics 23 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COGT or BBIO?

In the previous week, BridgeBio Pharma had 13 more articles in the media than Cogent Biosciences. MarketBeat recorded 18 mentions for BridgeBio Pharma and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat BridgeBio Pharma's score of 1.07 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BridgeBio Pharma 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or COGT?

In the previous week, Ascendis Pharma A/S had 35 more articles in the media than Cogent Biosciences. MarketBeat recorded 40 mentions for Ascendis Pharma A/S and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat Ascendis Pharma A/S's score of 0.49 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer EXEL or COGT?

In the previous week, Exelixis had 25 more articles in the media than Cogent Biosciences. MarketBeat recorded 30 mentions for Exelixis and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat Exelixis' score of 0.80 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 15 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Cogent Biosciences (COGT) Competitors

$34.37 -0.20 (-0.59%)

As of 10:24 AM Eastern

Compare

COGT vs. UTHR, GMAB, BBIO, ASND, and EXEL

Should you buy Cogent Biosciences stock or one of its competitors? Cogent Biosciences's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cogent Biosciences compare to United Therapeutics?

Cogent Biosciences (NASDAQ:COGT) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, United Therapeutics had 26 more articles in the media than Cogent Biosciences. MarketBeat recorded 31 mentions for United Therapeutics and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat United Therapeutics' score of 1.43 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
United Therapeutics	23 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Cogent Biosciences' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
United Therapeutics	41.56%	20.18%	17.98%

United Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
United Therapeutics	$3.18B	6.63	$1.33B	$27.95	17.60

94.1% of United Therapeutics shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cogent Biosciences presently has a consensus target price of $51.56, suggesting a potential upside of 49.13%. United Therapeutics has a consensus target price of $646.00, suggesting a potential upside of 31.30%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Cogent Biosciences on 13 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Genmab A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.74	$963M	$1.27	26.94
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Genmab A/S presently has a consensus price target of $39.50, suggesting a potential upside of 15.43%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 49.13%. Given Cogent Biosciences' higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Cogent Biosciences had 5 more articles in the media than Genmab A/S. MarketBeat recorded 5 mentions for Cogent Biosciences and 0 mentions for Genmab A/S. Cogent Biosciences' average media sentiment score of 1.70 beat Genmab A/S's score of 1.02 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Genmab A/S	Positive
Cogent Biosciences	Very Positive

Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 19.08% compared to Cogent Biosciences' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summary

Genmab A/S beats Cogent Biosciences on 11 of the 15 factors compared between the two stocks.

How does Cogent Biosciences compare to BridgeBio Pharma?

Cogent Biosciences (NASDAQ:COGT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Cogent Biosciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Cogent Biosciences has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
BridgeBio Pharma	$502.08M	29.79	-$724.93M	-$3.57	N/A

In the previous week, BridgeBio Pharma had 13 more articles in the media than Cogent Biosciences. MarketBeat recorded 18 mentions for BridgeBio Pharma and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat BridgeBio Pharma's score of 1.07 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BridgeBio Pharma	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences presently has a consensus target price of $51.56, indicating a potential upside of 49.13%. BridgeBio Pharma has a consensus target price of $101.53, indicating a potential upside of 32.71%. Given Cogent Biosciences' higher probable upside, equities research analysts plainly believe Cogent Biosciences is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Cogent Biosciences has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
BridgeBio Pharma	-97.03%	N/A	-61.19%

99.9% of BridgeBio Pharma shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cogent Biosciences and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Ascendis Pharma A/S had 35 more articles in the media than Cogent Biosciences. MarketBeat recorded 40 mentions for Ascendis Pharma A/S and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat Ascendis Pharma A/S's score of 0.49 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	6 Very Positive mention(s)	8 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ascendis Pharma A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.47	-$258M	$12.89	20.74
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Ascendis Pharma A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Ascendis Pharma A/S presently has a consensus price target of $310.05, indicating a potential upside of 15.99%. Cogent Biosciences has a consensus price target of $51.56, indicating a potential upside of 49.13%. Given Cogent Biosciences' higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Ascendis Pharma A/S has a net margin of 70.99% compared to Cogent Biosciences' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summary

Ascendis Pharma A/S beats Cogent Biosciences on 12 of the 14 factors compared between the two stocks.

How does Cogent Biosciences compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 14.46%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 49.13%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Exelixis has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Cogent Biosciences' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Cogent Biosciences	N/A	-84.47%	-47.72%

Exelixis has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.25	$782.57M	$3.18	18.41
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

In the previous week, Exelixis had 25 more articles in the media than Cogent Biosciences. MarketBeat recorded 30 mentions for Exelixis and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.70 beat Exelixis' score of 0.80 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	15 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Cogent Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Exelixis beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.02B	$3.99B	$7.21B	$12.66B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-16.00	12.25	272.68	25.23
Price / Sales	N/A	1,387.15	630.59	104.23
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	12.85	16.58	12.99	6.10
Net Income	-$328.94M	-$22.72M	$3.47B	$348.86M
7 Day Performance	-6.79%	-1.24%	-0.10%	-1.90%
1 Month Performance	-11.04%	11.25%	6.76%	1.96%
1 Year Performance	164.30%	53.08%	25.09%	15.30%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	2.6811 of 5 stars	$34.37 -0.6%	$51.56 +50.0%	+188.1%	$5.95B	N/A	N/A	80	Positive News
UTHR United Therapeutics	4.7448 of 5 stars	$512.88 0.0%	$646.00 +26.0%	+21.5%	$22.01B	$3.18B	18.35	1,400	Positive News Insider Trade
GMAB Genmab A/S	3.8543 of 5 stars	$33.02 -1.3%	$39.50 +19.6%	+32.2%	$20.86B	$3.72B	26.00	3,029	Positive News Analyst Upgrade Gap Up
BBIO BridgeBio Pharma	3.413 of 5 stars	$81.07 -0.5%	$100.79 +24.3%	+53.0%	$15.93B	$502.08M	N/A	400	Positive News Analyst Forecast
ASND Ascendis Pharma A/S	4.2994 of 5 stars	$251.95 -0.5%	$300.33 +19.2%	+34.2%	$15.80B	$814.57M	19.55	1,189	News Coverage Positive News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does Cogent Biosciences compare to United Therapeutics?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Summary

How does Cogent Biosciences compare to BridgeBio Pharma?

Summary

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Summary

How does Cogent Biosciences compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does Cogent Biosciences compare to United Therapeutics?

Does the media refer more to COGT or UTHR?

Which has more volatility & risk, COGT or UTHR?

Is COGT or UTHR more profitable?

Which has higher earnings & valuation, COGT or UTHR?

Do insiders and institutionals have more ownership in COGT or UTHR?

Do analysts rate COGT or UTHR?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Which has preferable earnings and valuation, GMAB or COGT?

Do analysts prefer GMAB or COGT?

Does the media favor GMAB or COGT?

Which has more volatility and risk, GMAB or COGT?

Do institutionals & insiders hold more shares of GMAB or COGT?

Is GMAB or COGT more profitable?

Summary

How does Cogent Biosciences compare to BridgeBio Pharma?

Which has more risk & volatility, COGT or BBIO?

Which has higher valuation & earnings, COGT or BBIO?

Does the media refer more to COGT or BBIO?

Do analysts recommend COGT or BBIO?

Is COGT or BBIO more profitable?

Do institutionals & insiders have more ownership in COGT or BBIO?

Summary

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Does the media prefer ASND or COGT?

Which has stronger earnings & valuation, ASND or COGT?

Which has more risk and volatility, ASND or COGT?

Do analysts rate ASND or COGT?

Is ASND or COGT more profitable?

Summary

How does Cogent Biosciences compare to Exelixis?

Do analysts rate EXEL or COGT?

Which has more risk and volatility, EXEL or COGT?

Do insiders and institutionals hold more shares of EXEL or COGT?

Is EXEL or COGT more profitable?

Which has preferable valuation & earnings, EXEL or COGT?

Does the media prefer EXEL or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools